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Antibodies (Abs) to CD20 and MHC class II antigen were found to exhibit a novel processing pathway after binding to the surface of
RL B-lymphoma cells. The Abs were ‘excreted’ as a part of large cytoplasmic fragments. These fragments formed at cell–cell
junctions, but gentle dispersal of the cells, to form a single-cell suspension of high viability, caused the release of most of the fragments.
This process also occurred in Raji cells and in three other B-lymphoma cell lines (of seven tested). Six B-lymphoblastoid cell lines
tested did not form these objects. Once they were recognised, the fragments could be identified in cell preparations by phase
contrast microscopy or after staining with Wright’s stain. They were induced by the binding of certain Abs, but not by most Abs
bound to the cell surface. The mode of formation, detailed morphology and function of these cytoplasmic fragments remain to be
determined. They are similar in many respects to the lymphoglandular bodies that have been described by pathologists for many
years, which are characteristic of B-cell lymphoma, but which have not previously been described in cell lines. This type of Ab
processing, if it occurs in patients, will have an impact on the therapeutic use of these Abs.
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CD20 is a B-cell-specific marker that has been used extensively as a
target for antibody (Ab) therapy in patients with B-cell lymphoma.
Unconjugated Abs have become established as standard therapy
(McLaughlin et al, 1998), and radiolabelled Abs, conjugated with
90Y, are significantly more effective than the unconjugated Abs
(Witzig et al, 2000). The processing of the Ab after binding to the
cell surface is an important factor that will affect its therapeutic
activity. We recently investigated the fate of anti-CD20 Abs after
binding to the surface of B-lymphoma cell lines (Michel and
Mattes, 2002). Using anti-CD20 (1F5) conjugated to the fluor-
ophore Alexa 488, the Ab was found to gradually accumulate in a
noncatabolic intracellular site. This site had the appearance of a
large juxtanuclear (JN) spot in Raji and Daudi cells, while in
Ramos cells the fluorescence was more dispersed, and consisted of
smaller cytoplasmic vesicles. In all three of these cell lines, the
location of the Ab was virtually identical to the steady-state
localisation of transferrin, as seen with a simultaneous rhodamine
label. These data indicate that anti-CD20 localises to the endocytic
recycling compartment (ERC), although its rate of transfer to this
compartment is much slower than that of transferrin. This result
was unexpected, in that anti-CD20 is widely considered to be a
noninternalising Ab; this apparent discrepancy can be explained
by the fact that intracellular accumulation of the Ab is slow, and
only prominent after many hours of incubation (generally
overnight).
The RL cell line differed from the other three cell lines tested, in
that prominent cytoplasmic accumulation of the Ab was not
evident, although initial cell surface binding was as strong as with
the other cell lines. In addition, long-term saturation experiments
with radiolabelled Ab revealed an apparent paradox: total uptake
of Ab per cell was much higher at 24h than at 1h, by a mean factor
of 2.5 (unpublished data), similar to the increase described
previously with Raji cells (Ong et al, 2001; Michel and Mattes,
2002). Since such Ab uptake in RL cells was not detected by
immunofluorescence (by FACS or microscopic analysis), the
implication of these results is that the Ab was taken up by RL
cells at some site that was not seen by immunofluorescence. In the
current study, we examined Ab uptake in RL cells more
thoroughly, using, initially, a more sensitive assay, namely
immunoperoxidase staining. By this method, and subsequently
by immunofluorescence, it was found that anti-CD20 Abs, and
certain but not all other Abs, accumulated in large shed
cytoplasmic fragments after binding to the cell surface. Production
of these cytoplasmic fragments was induced by Ab binding, and
occurred in most, but not all, B-lymphoma cell lines, to varying
degrees; it did not occur in B-lymphoblastoid cell lines.
The function of the CD20 antigen is not fully known, but it
appears to play a role in lymphocyte activation, and evidence
suggests that it may function as a Ca
2þ channel (Bubien et al,
1993). It is a tetraspan membrane protein, with only a small loop
present on the exterior of the cell (Zhou and Tedder, 1995). All Abs
recognise a single epitope, in competitive binding experiments,
although different Abs differ in their physiological effect (Zhou
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yand Tedder, 1995). Antibody binding induces the rapid redis-
tribution of nearly all of the CD20 to a low-density, detergent-
insoluble plasma membrane compartment (Polyak et al, 1998;
Semac et al, 2003).
MATERIALS AND METHODS
Cell lines, Abs and Ab conjugates
The B-lymphoma cell lines Raji, Ramos, and Daudi and the
lymphoblastoid cell lines RPMI-1788, RPMI-7666, IMP-9, SKW6.4,
GK-5 and EH IV were obtained from The American Type Culture
Collection (ATCC, Rockville, MD, USA). The RL cell line, a diffuse,
large-cell B-lymphoma cell line, was described previously (Hansen
et al, 1996), and is now available from ATCC. SU-DHL-4 and SU-
DHL-6 cell lines (Epstein et al, 1978) were provided by Dr AL
Epstein (University of Southern California Medical Center, Los
Angeles, CA, USA). The BJAB cell line (Schmid et al, 1993) was
obtained from Dr ES Vitetta (University of Texas Southwestern
Medical Center, Dallas, TX, USA). Cells were cultured as described
(Hansen et al, 1996; Ong et al, 1999). They were tested routinely for
mycoplasma by the Mycotect assay (Life Technologies, Grand
Island, NY, USA), and were negative. All of the Abs used were
described previously (Hansen et al, 1996; Ong et al, 1999). Anti-
CD147 (MA103) is produced by a hybridoma generated by us.
Anti-CD20 Abs (1F5 and 2B8) and anti-HLA-DR Abs (L243 and
IVA12) were produced by hybridomas obtained from ATCC. In
both cases, the Ab subclasses are IgG2a and IgG1, respectively.
Antibody 2B8, as obtained from ATCC, was found to consist of
primarily non-Ab-producing cells; therefore, Ab-producing cells
were cloned by limiting dilution before expansion. Rituximab is a
human/mouse chimeric Ab to CD20, derived from 2B8, which is a
product of IDEC Pharmaceuticals, and was purchased from Florida
Infusions (Palm Harbor, FL, USA). Anti-CD22 (LL2) and anti-
CD74 (LL1) Abs were provided by the Antibody Production
laboratory of Immunomedics, Inc. (Morris Plains, NJ, USA). Anti-
CD19 (HD37) was provided by Dr Ellen Vitetta. Control Abs of the
same subclasses were also tested, namely the IgG1 Ab MOPC-21
and the IgG2a Abs TA99 and MX352a. Rabbit anti-human IgM was
purchased from DAKO Corp. (#A425, IgG fraction, Carpinteria,
CA, USA). Both anti-CD20 Abs, anti-CD147, and a control Ab,
MX352a, were conjugated with Alexa 488, from Molecular Probes
(Eugene, OR, USA) as described previously (Michel and Mattes,
2002). Preparation of the Fab fragment of Ab 1F5, and its
conjugation with Alexa 488, was described previously (Michel and
Mattes, 2002). Antibodies were sterilised by passage through a
0.2mm pore size filter. Peroxidase staining utilised reagents from
Vector Laboratories (Burlingame, CA, USA), namely biotinylated
horse anti-mouse IgG, and a complex of streptavidin and
biotinylated peroxidase. For use with the rabbit anti-human IgM
antisera, we used a biotinylated anti-rabbit IgG from Vector Labs.
Immunoperoxidase staining
Cells (2.5 10
5) were incubated overnight in a well of a 24-well
plate in 0.5ml medium containing Abs at a concentration of
10mgml
 1. Cells were then transferred to a tube, pelleted,
suspended in 2.5ml of DPBS, 0.5% BSA, 10mM NaN3, and
cytocentrifuge slides were prepared, with a StatSpin Cytofuge 2
(Norwood, MA, USA), using 0.2ml per slide. After air drying,
slides were fixed with 4.0% formaldehyde in phosphate-buffered
saline (PBS) for 20min at room temperature. The formaldehyde
was prepared from depolymerised paraformaldehyde as described
(Farr and Nakane, 1981). After washing with DPBS, slides were
flooded and incubated for 10min with DPBS-BSA-N3 with or
without 0.15% saponin. All buffers used for washes and incuba-
tions in subsequent steps were also either with or without saponin,
as appropriate. After discarding the buffer, the spot of cells was
covered with 50ml biotinylated horse anti-mouse IgG (Vector
Labs), diluted 1:200, in the same buffer. For use with the rabbit
anti-mouse IgM, biotinylated anti-rabbit IgG was used. After 1h
incubation at 371C in a humid chamber, slides were washed once
rapidly and 2 10min with the same buffer. The cell spot was then
covered with 50ml ABC reagent (Vector Labs) and incubated 1h at
371C. After washing as above, the cell spot was covered with 0.1ml
DAB solution, prepared as follows. A 10mg tablet of DAB (Sigma
Chemicals, St Louis, MO, USA) was dissolved in 20ml 0.05 M Tris–
HCl, pH 7.2, and 6.6ml of 30% H2O2 was added. Saponin was not
included in this or subsequent steps. After 15min at room
temperature, slides were washed three times with PBS, once with
water, and air-dried. They were counterstained for 5min with Gill’s
haematoxylin (#GHS-1-32, Sigma Chemicals), washed with water,
air dried, and a coverslip was mounted with Cytoseal (VWR, West
Chester, PA, USA).
Immunofluorescence
Cells were generally incubated overnight with the directly
conjugated Ab at 10mgml
 1. The Fab fragment was used at
50mgml
 1. After two washes, they were examined in an Olympus
fluorescent microscope with a 100W mercury bulb. In some
experiments, smears were prepared, after suspending the cells in a
small volume of foetal bovine serum. The smears were fixed in
methanol for 10min, and examined with a loose coverslip. After
photographing cytoplasmic fragments, and recording the X and Y
coordinates of the slide holder, the slide was stained with Wright’s
stain, and the same cells were then re-examined. In some
experiments, cells were examined without washing away unbound
Ab, by transferring the cell suspension gently (so as not to disperse
cell clusters) directly to slides for observation. Representative
samples were examined with a Zeiss LSM 410 confocal microscope,
equipped with an argon–krypton laser.
Other methods
Wright’s staining was by standard methods, using stain from
Harleco (#740, purchased from VWR, West Chester, PA, USA).
Photographs were taken with an Olympus Microfire digital camera.
RESULTS
CD20-containing cytoplasmic fragments from RL cells
The immunoperoxidase staining method was intended to provide
greater sensitivity than the immunofluorescence assay, and to
thereby reveal the location of anti-CD20 Abs taken up by RL
lymphoma cells. Raji cells were used in preliminary experiments,
to develop the assay, since it was previously established, by
fluorescence, that anti-CD20 localised to a JN site in this cell line.
This same pattern of localisation in Raji cells was demonstrated by
the peroxidase method (Figure 1A). In RL cells, in contrast,
cytoplasmic peroxidase staining was much less prominent,
although small cytoplasmic vesicles were stained (Figure 1B).
However, large, apparently extracellular objects were very darkly
stained in RL cell preparations (Figure 1B, C). Some of these were
as large as cells, or larger, but they were heterogeneous in size, and
some were much smaller. The total number of these objects was
approximately 5% of the number of cells. Due to the very dark
peroxidase staining, the nature of the objects that were stained
could not be distinguished. Therefore, additional experiments were
performed in which peroxidase staining was made lighter, by
simply decreasing the time of the peroxidase reaction. From these
studies, it was found that the stained objects appeared to be large
cytoplasmic fragments, not containing a nucleus. Most of these
objects appeared to be bound to the outer surface of cells, but
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ysome were unattached. We note that the cytocentrifuge method
used tends to cause extensive clustering of cells that are not really
clustered, as the cells are deposited on the slide. Therefore, the fact
that the stained objects were often within cell clusters does not
indicate that such aggregates were present initially. We tentatively
refer to these objects as cytoplasmic fragments (CFs).
Staining experiments were also carried out in the absence of
saponin, in which case the Ab should be unable to cross
membranes. The CFs were also stained in this experiment,
but much less darkly than in the presence of saponin
(Figure 1D). Staining was variegated, with some areas of the CFs
much more darkly stained than others. We conclude that some of
the Ab in the CFs is not enclosed in a membrane. But since
the staining was much weaker than in the presence of saponin, the
majority of the bound 1F5 is apparently within a membrane-
enclosed compartment. In the experiment without saponin, there
was no staining of cytoplasmic vesicles, as expected. There was
sharp cell membrane staining in the absence of saponin
(Figure 1D), but only approximately 10% of the cells had this
membrane staining, which we cannot explain, but presumably is
due to a problem of accessibility and/or fixation. The membrane
staining was sharper in the absence of saponin than in its presence,
probably because saponin caused some disruption of the cell
membrane.
To further characterise these darkly stained objects, similar
experiments were performed by immunofluorescence, using a
directly labelled anti-CD20 Ab. As shown in Figure 2, similar very
brightly stained extracellular objects were seen by fluorescence.
Again, some of these were attached to cells, and others were
unattached. Since these cells were examined in suspension, the
artefactual clustering that occurs in cytocentrifuge preparations
was not a factor. In addition to the very bright CFs, the cell
membrane and small cytoplasmic vesicles were more weakly
stained, with most of the membrane staining having a cap-like
appearance, as shown (Figure 2A). Early time points from 1 to 5h
were examined, in an attempt to determine the origin of the CFs.
At these early time points, staining was heterogeneous, with some
cells stained in a ring pattern, but most being partially capped.
Small caps, as occur with strongly capping Abs such as anti-IgG
(Schreiner and Unanue, 1976), were not observed at any time
point. Fluorescent CFs were first visible at 4–5h, but increased in
frequency and size with time, and became much more prominent
after overnight incubation with the Ab. By visible light, using
phase contrast observation, the CFs were clearly different from
cells, so could be recognised by visible light only. They were
irregular in shape, nonrefractile (unlike viable cells) and appeared
to contain smaller vesicles. Fluorescent staining of the CFs was
variegated, as shown in Figure 2B. Cytoplasmic fragments were not
seen when cells were incubated with a control, nonreactive Ab of
the same subclass, conjugated in the same way. Moreover, cell
preparations incubated with control Abs or without Abs did not
contain CFs that could be recognised by visible light, indicating
that the CFs were induced by Ab binding. As an additional
specificity control, cells were incubated with Alexa 488-MX352a (a
nonreactive Ab) together with unconjugated 1F5, at 10mgml
 1.
This experiment was intended to eliminate the possibility that CFs
are induced by 1F5, and then stain nonspecifically with any Ab
conjugate. This control also was negative. To obtain better
resolution of the CFs, representative samples were examined on
a confocal microscope. This displayed the variegated staining
pattern more clearly, showing unstained areas as well as brightly
stained areas within the same CF (Figure 3A). The CFs contained
vesicle-like objects, having smooth, sharp boundaries, some of
which were stained, and others unstained. Those that were
unstained often appeared to have a fluorescent membrane, or to
be surrounded by diffuse fluorescent material within the CF.
Free and cell-bound CFs were counted: in one typical case, after
overnight incubation with 1F5, 65 of 102 CFs (64%) were
Figure 1 Immunoperoxidase staining of B-lymphoma cells after overnight incubation with anti-CD20 (1F5). Cells were deposited on cytocentrifuge slides,
fixed with formaldehyde, permeabilised with saponin, and stained with a biotinylated horse anti-mouse IgG, followed by a complex of streptavidin and
peroxidase. Observation was with an  40 objective, except as noted. (A) Raji cells, showing prominent staining of JN spots. (B) RL cells, showing dark
staining of apparently extracellular objects, referred to as CFs. (C) A lower-power photograph of RL cells ( 10), to show the general staining pattern. (D)
RL cells stained in the absence of saponin, to show antigen that is accessible without permeabilisation. Control Abs of the same subclass produced no brown
staining.
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yunattached to cells. Cells were sometimes counterstained with
propidium iodide, to identify dead cells. Cells having attached CFs
were virtually all viable cells. Also, the CFs themselves were
unstained by propidium iodide, indicating that they contain no
nucleus or nuclear fragments. A second Ab to CD20, rituximab,
was also conjugated to Alexa 488, and tested for comparison: the
staining pattern on RL cells after overnight incubation was
generally very similar to that of 1F5, although staining appeared
to be slightly brighter with rituximab. Immunoperoxidase experi-
ments were also performed with a second Ab to CD20, 2B8 (the
mouse IgG1 Ab that was the origin of rituximab): again, staining
was essentially the same as with 1F5. Since the CFs are
heterogeneous in size, it seemed possible that small, cell-free CFs
might be missed in our experiments, if they are too small to pellet
under our normal washing conditions. To investigate this
possibility, the supernatant obtained after the normal wash of
Ab-treated cells was subjected to a spin for 30min at 10000r.p.m.
No visible pellet was obtained, and no CFs were detected in the
pellet by microscopic observation. We conclude that essentially all
CFs are large enough to pellet with the cells.
To better characterise the morphology of these objects, they
were examined using Wright’s stain, after being first identified by
immunofluorescence. Cells were stained overnight with fluorescent
anti-CD20, then used to prepare smears, which were fixed with
methanol. Fluorescence remained bright in such preparations, and
CFs could be readily identified. They were photographed, and the
X and Y coordinates of the slide holder were recorded. The slides
were then stained with Wright’s stain, and the same CFs were re-
examined. Figure 4 shows the appearance of representative CFs. As
a demonstration of the method used, Figure 4A shows an example
of the fluorescent staining of two cell-bound CFs and one free CF,
and Figure 4B shows the same cells after staining with Wright’s
stain. Note the variegated fluorescent staining of the CFs. All of the
other cells or CFs shown in Figure 4C–K were, similarly, identified
initially by their bright fluorescence. Figure 4C shows a typical free
CF, which is the most common type of CF in these preparations. In
general, the CFs stained with Wright’s stain looked like
cytoplasmic fragments, but with variegated blue staining: some
areas were relatively dark blue, and others were very pale, often
with a slight pink tinge. They typically appeared to contain some
fibrous elements. A clear relationship between structures stained
by fluorescence and Wright’s stain was not apparent. Another
common type of CF seen was bound to a cell, but apparently
separate from that cell. Cytoplasmic fragments that appeared to be
‘budding’ from the cell, although relatively rare, are of particular
interest, since these provide some indication of the process by
which CFs are generated. Figures 4D–K, were chosen to shown
examples of the polymorphic ‘budding’ cells; Figures 4D–F show
RL cells, and Figures 4G–K show Raji cells, which produced
generally similar CFs, as described below. In all cases, bright
staining was localised to the CF and not to the normal part of the
cell. As shown, the relationship between the cell and the ‘budding’
CF is complex. The nature of this budding process remains to be
characterised, and electron microscopy is required to fully analyse
the process. In some Raji cells (Figure 4H, J and K), the CFs
seemed to be ‘budding’ from more than one location on the cell
surface. Many of the CFs were comparable in size to the cells to
which they were attached, which seems difficult to explain, but it
should be considered that the CFs may be produced not by a single
cell, but by a cluster of cells, a possibility which is strongly
supported by data presented below. After examining CFs in these
experiments, we were able to readily identify CFs by Wright’s
staining alone, in the absence of fluorescent staining.
Are other Abs delivered to CFs?
Using the immunoperoxidase method, similar experiments were
performed with six other Abs, namely mouse mAbs to CD19,
CD22, CD74, CD147, HLA-DR and rabbit anti-human IgM. Only
one other Ab stained CFs darkly, anti-HLA-DR (Ab L243). Such
staining was even darker than with anti-CD20 (data not shown).
L243 also stained JN spots and the cell surface, but this staining
was much weaker than the staining of CFs. Staining with an IgG1
Ab to HLA-DR, IVA12, produced results very similar to those
obtained with L243 (which is an IgG2a). Other Abs did not stain
Figure 2 Fluorescence of RL cells after overnight incubation with Alexa
488-1F5. (A) Fluorescence, showing one large unattached CF and a smaller
cell-bound CF, as well as weaker staining of the membrane and cytoplasmic
vesicles of most of the cells. The CFs are overexposed, in order to allow
membrane staining to be seen. (B) Dim visible light (using phase contrast)
together with fluorescence, showing the same cells. Observation was with
an  40 objective.
Figure 3 Appearance of a CF on a confocal microscope. RL cells were
incubated overnight with Alexa 488-1F5; a large CF attached to a cell is
shown. (A) The pinhole size was 20, giving a slice thickness (FWHM) of
1.5mm. (B) The pinhole size was 50, giving a slice thickness of 3.6mm, and
the laser power was increased to allow cell membrane staining to be seen.
B-lymphoma cytoplasmic fragments
RB Michel and MJ Mattes
1503
British Journal of Cancer (2004) 91(8), 1500–1507 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yCFs at all (CD19, CD22, CD74, anti-human IgM), or weakly stained
a small fraction of CFs (CD147). All of these Abs stained RL
cells, and some stained the cell surface as brightly or brighter
than 1F5.
To determine whether crosslinking was required to induce
CF formation, experiments were performed with the Fab fragment
of 1F5, conjugated to Alexa 488. The Fab fragment also was
delivered to CFs, which were very similar to those induced by
the intact Ab, although the intensity of fluorescence in the CFs was
considerably lower, and the CFs appeared to be somewhat smaller.
We conclude that crosslinking by Abs is not required to induce CF
production.
Are CFs induced by Ab binding?
The immunofluorescence experiments described above indicated
that CFs are induced by Ab binding, and are not present in control
cells. To confirm this conclusion, smears stained with Wright’s
stain were examined, since CFs have a characteristic morphology
that can be identified by Wright’s staining alone, as noted
above. Since CFs are rare, it was necessary to scan a large number
of cells, at least 500. In three experiments, the number
of morphologically distinct CFs in RL cell preparations, after
overnight incubation with 1F5, was 0.8–1.9% of the cell number.
This included both CFs that were cell bound, and CFs that were
unattached to cells. There were no CFs present in control cell
preparations. Cytoplasmic fragments identified solely by Wright’s
staining were also induced by anti-HLA-DR, but not by Abs to
CD22, CD74, or human IgM, all of which react with the surface of
RL cells. We conclude that the formation of CFs is induced by the
binding of particular Abs.
Production of CFs by other B-lymphoma and
B-lymphoblastoid cell lines
Six other B-cell lymphomas and six B-lymphoblastoid cell lines
were examined for the presence of CFs by both fluorescence and
peroxidase methods. A list of the cell lines tested is given in
Materials and Methods. All were tested with 1F5, and other Abs
were also tested on some of the cell lines. The results of both types
of assays were consistent, except as noted. After overnight
incubation, 1F5 localised to cytoplasmic vesicles in all of the cell
lines tested. Cytoplasmic fragments induced by 1F5 were clearly
seen in four of the B lymphomas, but were not detected in any of
the B-lymphoblastoid cell lines. Raji cells had the highest
expression of CFs, of the new cell lines, and the appearance of
CFs ‘budding’ from Raji cells, stained with Wright’s stain, is shown
in Figure 4. Figure 1A also shows three CFs from Raji cells: one in
the centre, one at the upper right, near the edge, and the third at
the lower right, close to the ‘A’. BJAB, SU-DHL-4 and SU-DHL-6
cells had low levels of CFs that were not as prominent. The number
of CFs in Raji cell preparations was comparable to that with RL
cells, but the size of the CFs was smaller. The lesser prominence of
Raji CFs compared to those of RL cells was mainly due to the dark,
homogeneous staining of JN spots in Raji cells (Figure 1A), which
competes for attention. Raji cells were stained with all of the six
Abs that had been tested on RL cells, and a control, nonreactive
Ab, by the peroxidase method; and were also stained with and
without saponin. Raji cells were also tested by immunofluores-
cence, using all of the Alexa 488 conjugates that had been tested on
RL cells, including the conjugate of the Fab fragment of 1F5. All
results were essentially the same as those obtained with RL cells,
except that the JN spot was stained by Alexa 488-anti-CD20 in Raji
cells, as described previously (Michel and Mattes, 2002) (in
Figure 4 Appearance of CFs from RL cells (A–F) or Raji cells (G–K) after staining with Wright’s stain. All CFs shown were first identified by
fluorescence, after overnight incubation with Alexa 488-1F5, on smears fixed with methanol. The location (X and Y coordinates) of fields containing typical
fluorescent CFs was recorded, photographs were taken, and the same objects were examined after Wright’s staining. (A) An example of fluorescent CFs,
showing one unattached and two cell-bound CFs. Observation was with dim visible light as well as fluorescence, in order to allow the cells to be seen.
Essentially all of the cells also had weaker staining of the cell membrane and cytoplasmic vesicles, as shown in Figure 2A, but this staining is not visible at this
exposure setting. (B) The same field stained with Wright’s stain. (C) An example of a cell-free CF. (D–K) Examples of CFs that appear to be in the process
of detachment from cells. In all cases, the fluorescence was over the part of the cell that was identified morphologically as a CE, as exemplified in Figure 3A.
Observation was with an  40 objective for (A, B), and an  100 objective for the other photographs.
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yaddition to the staining of CFs). The only other significant
difference was that anti-CD147 stained CFs from Raji cells, about
as darkly as 1F5, as seen with both peroxidase and immuno-
fluorescent staining. Since Alexa 488-anti-CD147 did not stain a JN
spot in these cells, the transport of Abs to CFs apparently does not
require accumulation of the Ab in the ERC, suggesting that Ab
internalisation may not be required. Also, while Alexa Fab of 1F5
still induced and stained CFs in Raji cells, quite similar to those
induced by the intact Ab in abundance and staining intensity, and
indistinguishable by morphology, the Fab fragment produced very
little staining of the JN spot, as described previously (Michel and
Mattes, 2002). These results suggest that formation of Ab-
containing CFs by Raji cells is independent of the accumulation
of the Ab in a JN spot. The lymphomas that did not produce CFs
were Daudi and Ramos. Daudi was stained with the same panel of
six Abs that was tested on RL and Raji cells: CFs were not detected
with any of the Abs, all of which stained the cell surface and/or
cytoplasmic vesicles. We note that the two B-lymphoma lines with
no CFs are also the two lines that normally have the lowest level of
clustering.
Although the lymphoblastoid lines did not display CFs, all were
stained by anti-CD20. The staining was of both the cell surface and
cytoplasmic vesicles, and was seen by both fluorescence and
peroxidase methods. Cytoplasmic staining was similar to the
staining pattern seen in Raji in some of these lines (RPMI-1788 and
EH IV), with a JN spot; and similar to Ramos in other lines (IMP-9,
SKW6.4, GP5, RPMI-7666), with a larger number of small, more
dispersed cytoplasmic spots.
Appearance of CFs in undisrupted cell clusters
Most B-lymphoma cell lines, including RL, Raji, and BJAB, grow
normally in large clusters, as do most of the B-lymphoblastoid cell
lines. With RL and Raji cells (but not with BJAB cells), these
clusters are readily dispersed by gentle pipetting and handling, so
when the cells are washed, after Ab incubations, a single-cell
suspension is obtained. Cytoplasmic fragments in undisrupted
clusters could be examined by fluorescence, because the specific
staining is so bright that it can be clearly seen without washing
away the unbound fluorescent Ab. In these experiments, after
overnight incubation with the Ab, the cells were transferred, as
gently as possible, directly to a slide for observation. The
appearance of RL cells in this type of experiment is shown in
Figure 5. The staining was almost entirely at the centre of the
clusters, and no cell-free CFs were observed. We conclude that CFs
are normally present only at the centre of cell clusters, and that
they are separated from cells only when the cells are dispersed, by
pipetting. With Raji cells, there was also staining at the centre of
cell clusters, but it was much less prominent than with RL cells,
mainly due to the bright staining of JN spots. Again, no cell-free
CFs were detected unless cell clusters were dispersed. These results
suggest that CFs form within cell clusters, and that the appearance
seen previously in RL and Raji cell preparations is a consequence
of mechanical disruption of the clusters. This interpretation can
explain the variation in the size of the CFs, and the fact that the
number of CFs is much less that the number of cells. That is, since
most or all of the clustered cells appeared to be adjacent to a CF, at
the centre of the cluster, it seems likely that all contributed to the
formation of the CF. However, when the cells were dispersed by
pipetting, the CFs usually detached from the cells, resulting in
either a free CF or a CF remaining attached to only one cell.
DISCUSSION
We have described a novel pathway taken by Abs binding to the
surface of B-cell lymphomas, transport to large extracellular
cytoplasmic fragments. They are formed only after the binding of
certain Abs, and these Ab accumulate in these structures in large
amounts. Thus, after overnight incubation of RL cells with anti-
CD20, the great majority of the bound Ab has been transported to
these CFs. If this type of Ab transport occurs in patients with B-cell
lymphoma, it would have an impact on the use of radiolabelled
anti-CD20 for cancer therapy, since the shedding of bound Abs
would tend to reduce the accumulation of radioactivity in the
cells. Inasmuch as cell debris may bind Ab nonspecifically, it is
important to emphasise the specificity controls that
were performed: the CFs were not stained by a nonreactive,
subclass-matched fluorescent Ab, even in the presence of an
unconjugated anti-CD20 Ab, which induces the production of CFs.
In addition, viability remained high (495%) throughout these
experiments, so formation of CFs was not associated with cell
death or deterioration. Since CFs were observed in cultured cells
transferred directly onto a slide, and examined in suspension,
there is essentially no possibility that they are the artefact of
handling. The appearance of CFs varied markedly between
different cell lines: they were most prominent in RL cells, but
were also seen in four other B-lymphoma cell lines, of a total of
seven that were tested. Raji cells produced CFs, but were different
from RL cells in that RL cells shed most of the bound Ab in CFs,
while Raji cells retained a large fraction of the bound Ab in a JN
spot (Michel and Mattes, 2002).
Figure 5 Fluorescence of RL cells after overnight incubation with Alexa
488-1F5. Cells were examined without washing away unbound Ab, and
were handled as gently as possible, to leave cell clusters intact. (A)
Fluorescence. (B) Dim visible light (using phase contrast) together with
fluorescence, showing the same cells. Fluorescence is concentrated in the
centre of a cluster of cells. Control Ab conjugates of the same subclass
produced no significant staining. Observation was with an  40 objective.
B-lymphoma cytoplasmic fragments
RB Michel and MJ Mattes
1505
British Journal of Cancer (2004) 91(8), 1500–1507 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yThe results presented are descriptive, and much additional
investigation is required in order to understand the biological
and clinical significance of CF production. They appear to be
relatively common in cell lines, but it is important to know if CFs
are produced in primary tumours. Studies are in progress to
determine if CFs are present in mouse xenografts of RL and
Raji tumours after injection of anti-CD20 or anti-HLA-DR Abs.
Since many patients receive therapy with anti-CD20 (rituximab), it
may be possible to detect such structures in clinical specimens.
Indeed, Kennedy et al (2004) recently described cell clusters in the
blood of chronic lymphocytic leukaemia patients that had been
infused (for 7h) with rituximab. In these cell aggregates, which are
strikingly similar to the clusters shown in Figure 5, B cells
are clustered around ‘debris’ which contains a large amount
of the injected Ab and complement component C3. Their data
also suggested that the Ab and bound antigen were stripped from B
cells, which therefore became CD20-deficient while continuing to
circulate in the blood. This result is consistent with our data, since
membrane staining decreased in intensity as bright CFs formed.
While Kennedy et al (2004) did not observe similar events in
in vitro experiments, after a 7h incubation with Ab, and therefore
argued that macrophage-lineage cells were necessary for
CD20 stripping to occur, there are two possible explanations for
this apparent inconsistency. First, primary CLL cells incubated
in vitro, as used by Kennedy et al (2004), are likely to not behave
like healthy cells in vivo, even though the incubation period is
relatively short and cell death has not yet occurred. Second, there
may be differences between CLL cells and the non-Hodgkin’s
lymphoma cell line RL, which was used in most of
our experiments. Kennedy et al (2004) emphasised the role of
complement in the process of CD20 removal from the cell surface,
but did not provide direct evidence that complement was required.
Our results were similar with IgG1 and IgG2a Abs, which
strongly suggests that complement activation is not a significant
factor, since IgG1 Abs do not activate complement (Goding,
1983). (In our experiments, the available complement would be
from the foetal bovine serum in tissue culture medium; this
would not be likely to have high complement activity, but
may have some complement components.) Since the CFs
contain certain Abs, but not all, there is a selective process for
delivering Abs to this site, and it is important to test Abs to a
wide range of other antigens. Both CD20 and MHC class II antigens
are known to be enriched in membrane lipid rafts; for MHC
class II antigens this is a spontaneous association (Anderson
et al, 2000), while for CD20 this association is induced by Ab
binding (Petrie and Deans, 2002). There is also evidence for a
physical association of MHC class II antigens and CD20 (Le ´veille ´
et al, 1999).
These results explain previous paradoxical Ab uptake results,
which were described in the first section. That is, in prolonged
incubations of RL cells with saturating concentrations of
radiolabelled 1F5, it was found that uptake of the Ab was much
higher at 24h than at 1h, yet such an increase was not detected in
immunofluorescence experiments by FACS analysis of individual
cells. This result is expected if Abs are delivered primarily to CFs.
The Abs present in the CFs pellet together with the cells, and
therefore are detected as bound radioactive Abs. In contrast, such
Ab uptake would not significantly affect the FACS results, since a
small fraction of the cells have bound CFs, and many of the CFs are
cell-free at the time of analysis. Such cell-free CFs may or may not
be counted as cells, depending on their size, but even if they were
counted they would be recorded as a small number of very bright
objects, and hence would have little if any impact on the overall
FACS profile.
It is uncertain whether the Ab is delivered to the CFs
directly from the cell surface or after internalisation. Some Ab
does go to intracellular vesicles, but it seems most likely that
the CFs are produced by shedding of capped Ab. Although
shedding is often cited as an alternative fate of capped
Ab (Schreiner and Unanue, 1976; Loor, 1980) (in addition to the
predominant endocytotic pathway), the shedding of large CFs as
described herein has not been described previously, to our
knowledge. Spontaneous shedding (in the absence of any ligand
binding) of large CFs from viable cells has been described in
certain circumstances (Black, 1980; Loor, 1980; Kaplan and Keogh,
1982). Such shedding has been attributed to the pinching off of
microvilli or other membrane protrusions. Since the shedding in
our studies was dependent on Ab binding, it is distinct from the
types of spontaneous shedding that have been described.
Fritzsching et al (2002) described the release of membranous
microparticles, consisting of both exosomes and larger micro-
vesicles, from T-cell lines upon activation. These microparticles
selectively contained CD81, a tetraspanin; although CD20 is not in
the tetraspanin family, it does share the property of having four
transmembrane regions. We note also that circulating CD20 in the
serum of non-Hodgkin’s lymphoma patients was recently de-
scribed (Giles et al, 2003); this antigen appeared to be in the form
of small membrane fragments, and did not require Ab treatment
for induction, but some relationship with the shedding process
described here is possible.
Morphologically similar objects have been described previously,
for many years, under the name of lymphoglandular bodies
(LGBs) or So ¨derstro ¨m bodies (So ¨derstro ¨m, 1968; Flanders et al,
1993; Bangerter et al, 1997; Stern et al, 2001). These are well
established in the pathology literature, although there is no
previous report of their production by cultured cell lines, and also
no report of Ab delivery to these structures. Lymphoglandular
bodies are considered characteristic of B-cell lymphomas, and are
an aid in identification of this tumour type. They are defined as
large, cell-free cytoplasmic fragments, sometimes containing
organelles, with a diameter ranging from 2 to 7mm in smears.
Although the recent literature emphasises the presence of LGBs in
tumours, there are older reports that they also occur in normal
lymphoid tissue (Williamson, 1950; So ¨derstro ¨m, 1968). While
LGBs have been often dismissed as an artefact of handling
(So ¨derstro ¨m, 1968), this remains an open question. Although
speculative, it seems possible, and perhaps likely, that the CFs
described here are in fact LGBs.
A basic question is whether the CFs are naturally detached from
the cells, or whether they are cytoplasmic extensions that become
detached during handling procedures. If CFs form initially
as filopodia-like extensions, which are intertwined with those of
adjacent cells, then such extensions may be fragile, and may
detach from the cells due to handling. Our results are not
inconsistent with this possibility, since free CFs were seen only
after washing the cells, and since intact, unwashed clusters had
Ab localised only at the centre of the clusters. However, it
seems unlikely that cytoplasmic extensions could be torn from a
cell without killing that cell. Since the viability of our cell
preparations was generally high, 495%, and was not affected
by 1F5 binding, this possibility seems unlikely. In some experi-
ments, dead cells were counterstained with propidium iodide:
dead cells were never bound to CFs, and the cells bound to
fluorescent CFs were essentially all viable cells. Electron
microscopy may help to resolve this question. It should be
emphasised, in any case, that the dispersal of cell clusters and
CFs resulted from standard methods used to wash away unbound
Ab. The development of CFs in the centre of cell clusters, in
RL cell preparations, probably explains characteristics such
as their heterogeneity in size, and the fact that a very small
fraction of the cells have bound CFs. In the intact cell clusters
staining appeared quite homogeneous, with essentially all of the
cells being adjacent to a CF at the centre. The heterogeneity that
appears after dispersal may thus reflect the fact that the CFs break
apart unevenly, resulting in CFs of varying size, both cell-bound
and free.
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